{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:05:01Z","timestamp":1790255101767,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP190002"],"award-info":[{"award-number":["RP190002"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201321","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:58:14Z","timestamp":1786492694000},"page":"201321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["StagX1, an isoquinolinone compound, selectively targets CES1-positive Ewing sarcoma cells as a potential therapeutic agent"],"prefix":"10.1016","volume":"34","author":[{"given":"Nenggang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3665-5693","authenticated-orcid":false,"given":"Scott R.","family":"Gilbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9680-4614","authenticated-orcid":false,"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-835X","authenticated-orcid":false,"given":"Debananda","family":"Pati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201321_bib1","first-page":"348","article-title":"Management of recurrent or refractory Ewing sarcoma: A systematic review of phase II clinical trials in the last 15 years","volume":"18","author":"Xu","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omton.2026.201321_bib2","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2147\/OTT.S170585","article-title":"Management of recurrent Ewing sarcoma: challenges and approaches","volume":"12","author":"Van Mater","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.omton.2026.201321_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100653","article-title":"Synthesis and Evaluation of a Class of Compounds Inhibiting the Growth of Stromal Antigen 2 (STAG2)-Mutant Ewing Sarcoma Cells","volume":"17","author":"Zhang","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.omton.2026.201321_bib4","article-title":"Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia","volume":"11","author":"Karsa","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201321_bib5","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1124\/mol.108.045963","article-title":"Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening","volume":"73","author":"Madoux","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.omton.2026.201321_bib6","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1210\/jc.2008-2163","article-title":"Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists","volume":"94","author":"Doghman","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.omton.2026.201321_bib7","first-page":"91","article-title":"The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics","volume":"20","author":"Li","year":"2022","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.omton.2026.201321_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2006.07.001","article-title":"Structure, function and regulation of carboxylesterases","volume":"162","author":"Satoh","year":"2006","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.omton.2026.201321_bib9","first-page":"143","article-title":"The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol","volume":"29","author":"Merali","year":"2014","journal-title":"Drug Interact"},{"key":"10.1016\/j.omton.2026.201321_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.omton.2026.201321_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110097","article-title":"In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir","volume":"365","author":"Zhang","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.omton.2026.201321_bib12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.omton.2026.201321_bib13","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2174\/0929867325666171204155558","article-title":"Carboxylesterase Inhibitors: An Update","volume":"25","author":"Zou","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.omton.2026.201321_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s13238-017-0437-z","article-title":"Carboxylesterases in lipid metabolism: from mouse to human","volume":"9","author":"Lian","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.omton.2026.201321_bib15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1124\/dmd.120.000065","article-title":"Natural Products as Modulators of CES1 Activity","volume":"48","author":"Qian","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omton.2026.201321_bib16","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1124\/dmd.106.009381","article-title":"Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine","volume":"34","author":"Imai","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omton.2026.201321_bib17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.lfs.2007.07.026","article-title":"Carboxylesterase in the liver and small intestine of experimental animals and human","volume":"81","author":"Taketani","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.omton.2026.201321_bib18","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.bcp.2005.09.002","article-title":"Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma","volume":"70","author":"Li","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.omton.2026.201321_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fphar.2014.00231","article-title":"How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion","volume":"5","author":"Kell","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omton.2026.201321_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163624","article-title":"Interfering with lipid metabolism through targeting CES1 sensitizes hepatocellular carcinoma for chemotherapy","volume":"8","author":"Li","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201321_bib21","article-title":"Characterization of the interaction between the cohesin subunits Rad21 and SA1\/2","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201321_bib22","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1083\/jcb.200801157","article-title":"A handcuff model for the cohesin complex","volume":"183","author":"Zhang","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omton.2026.201321_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1124\/dmd.121.000633","article-title":"Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice","volume":"50","author":"Qin","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omton.2026.201321_bib24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Progr. Biomed."},{"key":"10.1016\/j.omton.2026.201321_bib25","doi-asserted-by":"crossref","DOI":"10.4172\/1948-5956.1000517","article-title":"Separase Inhibitor Sepin-1 Inhibits Foxm1 Expression and Breast Cancer Cell Growth","volume":"10","author":"Zhang","year":"2018","journal-title":"J. Cancer Sci. Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:35:29Z","timestamp":1790253329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001979"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201321","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"StagX1, an isoquinolinone compound, selectively targets CES1-positive Ewing sarcoma cells as a potential therapeutic agent","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201321"}}